TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report released on Monday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ:TXMD opened at $1.66 on Monday. TherapeuticsMD has a twelve month low of $1.43 and a twelve month high of $3.42. The company has a 50-day moving average of $1.76 and a 200-day moving average of $1.96.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The company had revenue of $0.23 million for the quarter.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TXMD. ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD during the 4th quarter valued at $612,000. Prosperity Consulting Group LLC acquired a new stake in TherapeuticsMD during the first quarter valued at $56,000. Finally, Clearline Capital LP grew its stake in TherapeuticsMD by 18.9% in the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock valued at $1,025,000 after purchasing an additional 101,282 shares in the last quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.